
Global Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Respiratory Syncytial Virus Vaccine for the Elderly market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Respiratory Syncytial Virus Vaccine for the Elderly market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Respiratory Syncytial Virus Vaccine for the Elderly market include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Respiratory Syncytial Virus Vaccine for the Elderly, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Respiratory Syncytial Virus Vaccine for the Elderly, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Syncytial Virus Vaccine for the Elderly, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Respiratory Syncytial Virus Vaccine for the Elderly market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Respiratory Syncytial Virus Vaccine for the Elderly sales, projected growth trends, production technology, application and end-user industry.
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company
GSK
Icosavax
Moderna
Pfizer
RNAimmune
Sanofi
Advaccine
Daiichi Sankyo
Immorna
Blue Lake Biotechnology
Clover Biopharma
Innorna
Starna Therapeutics
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type
Recombinant Protein Vaccine
Nucleic Acid Vaccines
Others
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Respiratory Syncytial Virus Vaccine for the Elderly status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Respiratory Syncytial Virus Vaccine for the Elderly market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Respiratory Syncytial Virus Vaccine for the Elderly significant trends, drivers, influence factors in global and regions.
6. To analyze Respiratory Syncytial Virus Vaccine for the Elderly competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for the Elderly market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Syncytial Virus Vaccine for the Elderly industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Respiratory Syncytial Virus Vaccine for the Elderly in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Respiratory Syncytial Virus Vaccine for the Elderly market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Respiratory Syncytial Virus Vaccine for the Elderly market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Respiratory Syncytial Virus Vaccine for the Elderly market include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Respiratory Syncytial Virus Vaccine for the Elderly, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Respiratory Syncytial Virus Vaccine for the Elderly, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Syncytial Virus Vaccine for the Elderly, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Respiratory Syncytial Virus Vaccine for the Elderly market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Respiratory Syncytial Virus Vaccine for the Elderly sales, projected growth trends, production technology, application and end-user industry.
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company
GSK
Icosavax
Moderna
Pfizer
RNAimmune
Sanofi
Advaccine
Daiichi Sankyo
Immorna
Blue Lake Biotechnology
Clover Biopharma
Innorna
Starna Therapeutics
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type
Recombinant Protein Vaccine
Nucleic Acid Vaccines
Others
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Respiratory Syncytial Virus Vaccine for the Elderly status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Respiratory Syncytial Virus Vaccine for the Elderly market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Respiratory Syncytial Virus Vaccine for the Elderly significant trends, drivers, influence factors in global and regions.
6. To analyze Respiratory Syncytial Virus Vaccine for the Elderly competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for the Elderly market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Syncytial Virus Vaccine for the Elderly industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Respiratory Syncytial Virus Vaccine for the Elderly in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2020-2031)
- 1.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (2020-2031)
- 1.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
- 2.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
- 2.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
- 2.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
- 2.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
- 3 Respiratory Syncytial Virus Vaccine for the Elderly Market by Company
- 3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Revenue Ranking in 2024
- 3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2020-2025)
- 3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Company (2020-2025)
- 3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price by Company (2020-2025)
- 3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Ranking (2023-2025)
- 3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Manufacturing Base and Headquarters
- 3.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Product Type and Application
- 3.8 Global Respiratory Syncytial Virus Vaccine for the Elderly Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Respiratory Syncytial Virus Vaccine for the Elderly Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
- 4.1 Respiratory Syncytial Virus Vaccine for the Elderly Type Introduction
- 4.1.1 Recombinant Protein Vaccine
- 4.1.2 Nucleic Acid Vaccines
- 4.1.3 Others
- 4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type
- 4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Type (2020-2031)
- 4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Type (2020-2031)
- 4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type
- 4.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Type (2020-2031)
- 4.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type (2020-2031)
- 5 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
- 5.1 Respiratory Syncytial Virus Vaccine for the Elderly Application Introduction
- 5.1.1 Hospital
- 5.1.2 Centers for Disease Control and Prevention
- 5.1.3 Others
- 5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application
- 5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume by Application (2020-2031)
- 5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Share by Application (2020-2031)
- 5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application
- 5.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Application (2020-2031)
- 5.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application (2020-2031)
- 6 Respiratory Syncytial Virus Vaccine for the Elderly Regional Sales and Value Analysis
- 6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2020-2031)
- 6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2020-2025
- 6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2026-2031)
- 6.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region (2020-2031)
- 6.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region: 2020-2025
- 6.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Region (2026-2031)
- 6.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2020-2031)
- 6.6.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2020-2031)
- 6.7.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2020-2031)
- 6.9.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Country, 2024 VS 2031
- 7 Respiratory Syncytial Virus Vaccine for the Elderly Country-level Sales and Value Analysis
- 7.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
- 7.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2025)
- 7.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2026-2031)
- 7.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2020-2031)
- 7.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2020-2025)
- 7.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.9.2 France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.16.2 China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.19.2 India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Comapny Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 Icosavax
- 8.2.1 Icosavax Comapny Information
- 8.2.2 Icosavax Business Overview
- 8.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.2.5 Icosavax Recent Developments
- 8.3 Moderna
- 8.3.1 Moderna Comapny Information
- 8.3.2 Moderna Business Overview
- 8.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.3.5 Moderna Recent Developments
- 8.4 Pfizer
- 8.4.1 Pfizer Comapny Information
- 8.4.2 Pfizer Business Overview
- 8.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.4.5 Pfizer Recent Developments
- 8.5 RNAimmune
- 8.5.1 RNAimmune Comapny Information
- 8.5.2 RNAimmune Business Overview
- 8.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.5.5 RNAimmune Recent Developments
- 8.6 Sanofi
- 8.6.1 Sanofi Comapny Information
- 8.6.2 Sanofi Business Overview
- 8.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.6.5 Sanofi Recent Developments
- 8.7 Advaccine
- 8.7.1 Advaccine Comapny Information
- 8.7.2 Advaccine Business Overview
- 8.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.7.5 Advaccine Recent Developments
- 8.8 Daiichi Sankyo
- 8.8.1 Daiichi Sankyo Comapny Information
- 8.8.2 Daiichi Sankyo Business Overview
- 8.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.8.5 Daiichi Sankyo Recent Developments
- 8.9 Immorna
- 8.9.1 Immorna Comapny Information
- 8.9.2 Immorna Business Overview
- 8.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.9.5 Immorna Recent Developments
- 8.10 Blue Lake Biotechnology
- 8.10.1 Blue Lake Biotechnology Comapny Information
- 8.10.2 Blue Lake Biotechnology Business Overview
- 8.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.10.5 Blue Lake Biotechnology Recent Developments
- 8.11 Clover Biopharma
- 8.11.1 Clover Biopharma Comapny Information
- 8.11.2 Clover Biopharma Business Overview
- 8.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.11.5 Clover Biopharma Recent Developments
- 8.12 Innorna
- 8.12.1 Innorna Comapny Information
- 8.12.2 Innorna Business Overview
- 8.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.12.5 Innorna Recent Developments
- 8.13 Starna Therapeutics
- 8.13.1 Starna Therapeutics Comapny Information
- 8.13.2 Starna Therapeutics Business Overview
- 8.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
- 8.13.5 Starna Therapeutics Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
- 9.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales Mode & Process
- 9.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
- 9.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.